23.10.2013 Views

Section 2 - FTSE

Section 2 - FTSE

Section 2 - FTSE

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

THE VALUE PLAY OF 130/30 STRATEGIES<br />

76<br />

Ric Thomas, a senior managing director of State Street Global<br />

Advisors (SSgA) and department head of the US enhanced equity<br />

group, estimates that at any particular time only 10 or 15 names in<br />

the Russell 1000 are specials subject to higher borrowing costs.<br />

Even for the small capitalisation Russell 2000 Index, he reckons<br />

85% of the names are general collateral. With so much scope for<br />

shorting general collateral stocks, 130/30 managers either avoid<br />

specials altogether or take small positions in just a few names.<br />

Leverage can cut both ways, of course.<br />

“We believe in active management,” says<br />

Bondurant, “If you have a manager that<br />

doesn’t have that skill in the first place<br />

130/30 is giving him another shot at<br />

getting it wrong.”<br />

team provides advice, analysis, prime broker and securities<br />

lending services to managers who run 130/30 portfolios.<br />

Although Darrell Riley, head of global institutional<br />

marketing at T. Rowe Price, accepts the logic behind 130/30<br />

structures he remains leery of its practical application,<br />

particularly for fundamental managers who often lack the<br />

quantitative tools and risk management systems needed to<br />

handle a short book. He notes that short positions<br />

consume a disproportionate share of a manager’s<br />

emotional energy, too. “It’s the exception rather than the<br />

rule that people are good at it,” Riley says. T. Rowe Price<br />

does not offer 130/30 portfolios today and has no<br />

immediate plans to do so.<br />

Riley sees 130/30 products positioned as high conviction<br />

long strategies with selective use of shorts to capture the<br />

full benefit of a manager’s research knowledge. On the<br />

quant side, it works remarkably well for as long as the<br />

quantitative model works.“Quants are fine when there is<br />

good factor stability and when you combine that with<br />

130/30, it’s fantastic,” Riley says, “But when there is a<br />

turning point, they may really suffer.” It’s no secret that<br />

quantitative 130/30 managers hit a rough patch during the<br />

market turmoil in July and August.<br />

Track records in 130/30 are still short, but so far, UBS,<br />

which has $2.25bn under management, has delivered<br />

about double the excess return of its long only portfolios.<br />

From inception in September 2005 through the end of<br />

June, its institutional 130/30 product is up 17.93%,<br />

compared to 15.76% for the equivalent long only<br />

portfolio and 14.32% for the Russell 1000, the benchmark<br />

for both. At 4.33%, the tracking error has come in at the<br />

low end of the 4%-8% target range, which Bondurant<br />

attributes to unusually low market volatility through<br />

most of the period.<br />

Investors don’t get a free lunch, however. 130/30<br />

portfolios bear incremental transaction costs because they<br />

deploy 60% more capital and have correspondingly higher<br />

portfolio turnover. Managers charge higher fees, too. For<br />

its retail 130/30 product, UBS charges 150bps—about<br />

35bps more than for the equivalent long only vehicle.<br />

Institutional fees are lower, of course, but 130/30 products<br />

still command a 45% premium over long only fees. The<br />

portfolios incur stock borrowing and financing costs, too,<br />

which Bondurant estimates at 15bps provided almost all<br />

the shorts come from the general collateral pool. On<br />

balance, a retail UBS investor pays an extra 50bps for a<br />

shot at up to 300bps of excess return.<br />

Borrowing from the hedge fund world, institutional<br />

130/30 fees often include a performance element although<br />

it typically doesn’t kick in unless the manager beats the<br />

benchmark return. Brad Taylor, global head of investment<br />

finance and hedge fund services at RBC Dexia, says<br />

institutions are happy to pay for alpha but not for<br />

strategies that only deliver repackaged beta. “Institutions<br />

are looking for the benefit of a long- short approach but<br />

they are increasingly seeking this exposure in a more<br />

modest cost structure,” Taylor says. Institutions like the<br />

transparency and controlled risk profile 130/30 portfolios<br />

offer, too.<br />

So far, most 130/30 products are benchmarked to broad<br />

indices, including the MSCI World, the Standard & Poor’s<br />

500 and the Russell 1000. For large capitalisation indices<br />

like these, even the smaller names a 130/30 manager might<br />

want to sell short are usually available in the general<br />

collateral pool.<br />

NOVEMBER/DECEMBER 2007 • <strong>FTSE</strong> GLOBAL MARKETS

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!